Tufts Center study shows significant time savings in delivering therapies to patients

Integrated Thermo Fisher services shown to cut drug development timelines by nearly three years

Thermo Fisher Scientific has announced new research from the Tufts Center for the Study of Drug Development (Tufts CSDD) demonstrating that its Accelerator™ Drug Development 360° contract development and manufacturing organization (CDMO) and clinical research organization (CRO) solutions can significantly shorten drug development timelines and improve financial outcomes for biotech and biopharma companies worldwide. The independent analysis shows that using Thermo Fisher’s integrated services from Phase I through Phase III clinical development can potentially reduce overall development time by up to 34 months, helping sponsors navigate complex regulatory pathways, control costs and bring new medicines to patients faster.

The challenge of traditional, fragmented drug development

Biotech and biopharma companies face rising development costs, increasing regulatory complexity and intense pressure to deliver safe, effective therapies more quickly. Traditionally, drug developers have relied on multiple, separate supplier partners for bioprocessing, clinical development, clinical supply and manufacturing solutions. This decentralized model often leads to operational inefficiencies, miscommunication between functions and delays across the development lifecycle.

These delays can have substantial financial consequences. Each month of delay in a Phase III clinical trial can result in up to $8 million in lost revenue due to shortened market exclusivity and deferred market entry, underscoring the need for more streamlined, coordinated approaches.

Tufts CSDD study highlights benefits of integrated CDMO and CRO services

The Tufts CSDD study evaluated the impact of working with an integrated partner that combines CDMO and CRO capabilities across the clinical development continuum. The research demonstrates that integrated services can help streamline the complex journey from early clinical studies through late-stage development and commercialization.

According to the findings, using integrated services from Phase I through Phase III can reduce drug development timelines by up to 34 months compared with more fragmented approaches. This acceleration reflects the advantages of unified oversight, coordinated planning and consistent communication across manufacturing, clinical research and clinical supply chain activities.

Accelerator Drug Development 360° model and real-world adoption

Accelerator Drug Development offers a customizable suite of manufacturing, clinical research and clinical supply chain services that can be tailored to the needs of each program at every stage of development. The 360° model is designed to integrate bioprocessing, clinical operations and supply logistics within a single, coordinated framework.

To date, more than 120 biotech and biopharma companies have partnered with Thermo Fisher across its integrated CDMO and CRO solutions. These collaborations span more than 350 protocols across a wide range of therapeutic areas and modalities, including small molecules, large molecules and advanced therapies.

Time savings and financial impact for drug sponsors

The Tufts CSDD analysis found that integrated CRO/CDMO services can generate substantial financial benefits for drug sponsors. By compressing development timelines and reducing operational inefficiencies, integrated services can deliver up to $63 million in net financial benefits, representing a return on investment of up to 113 times the initial investment.

Researchers examined multiple scenarios across different phases of drug development and varying levels of investment in integrated services. Across all scenarios, they observed demonstrable time savings and positive return on investment, highlighting the broad applicability of integrated models for sponsors pursuing diverse development strategies.

How integration drives value across the development lifecycle

The study attributes these benefits to several core features of integrated development models. Cross-functional program coordination ensures that clinical, manufacturing and supply chain activities are aligned with overall development goals and timelines. Enhanced collaboration and oversight help identify and resolve issues earlier, while integrated planning and communication reduce the risk of delays caused by siloed decision-making.

By consolidating key functions under a single, integrated framework, sponsors can improve operational efficiency, reduce handoff-related risks and maintain clearer visibility into program progress from early clinical stages through late-phase trials.

Expert perspective on integrated development strategies

The study’s lead author, Dr. Joseph DiMasi, director of economic analysis and research associate professor at Tufts University, emphasized the strategic importance of integration for modern drug development. He noted that the cost of developing new drugs is exacerbated by operational inefficiencies arising from the separation of clinical research, drug manufacturing and supply chain functions.

Dr. DiMasi’s analysis indicates that fully integrated service provision yields the greatest financial benefit for sponsors. However, the research also shows that even partial integration can deliver significant value, particularly in the later phases of clinical development where timelines and costs are most critical. Drug sponsors are encouraged to consider the degree of integration that will deliver the most value for their specific programs and portfolios.

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>